Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis

Taro Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Atopic Dermatitis

Treatments: Drug: Protopic - Tacrolimus 0.1%; Drug: Tacrolimus Vehicle manufactured by Taro; Drug: Tacrolimus 0.1% manufactured by Taro

Study type: Interventional

Funder types: Industry

Identifiers

NCT00833079

TACR-0707

Details and patient eligibility

About

The primary objectives are to establish the therapeutic equivalence of tacrolimus ointment 0.1%, manufactured by Taro Pharmaceuticals Inc. and Protopic® (tacrolimus), 0.1% topical ointment (Astellas Pharma US, Inc.) and to show superiority over vehicle in the treatment of moderate to severe atopic dermatitis.

The secondary objectives are to compare the adverse event (AE) profiles of the two ointments and to investigate their systemic absorption at steady state.

Enrollment: 500 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or non-pregnant, non-lactating female, 18 years of age or older.
• Patient has documented evidence that they have been unresponsive to alternative more traditional therapies such as topical corticosteroids, or in the investigators opinion, such first line therapy would be deemed inadvisable because of potential risks to the patient.
• If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom, IUD, oral, transdermal, injected or implanted hormonal contraceptives).
• Have confirmed diagnosis of atopic dermatitis using the diagnostic features as described by Hanifin and Rajka.
• Have an IGSA score of 3 (moderate) or 4 (severe)
• Have an affected Body Surface Area (BSA) of at least 20%
• Have a minimum Eczema Area and Severity Index (EASI) score of at least 15

Exclusion criteria

• Mild atopic dermatitis as defined by IGSA score of 0 (clear), 1 (almost clear), or 2 (mild) OR %BSA affected less than 20% OR EASI Score of less than 15.
• Clinically infected atopic dermatitis at the baseline visit. Tacrolimus is not indicated for the treatment of clinically infected atopic dermatitis
• Any dermatological condition other than atopic dermatitis that in the Investigator's opinion may interfere with the evaluation of the patient's atopic dermatitis
• Females who are pregnant, lactating or likely to become pregnant during the study.
• History of allergy or sensitivity to tacrolimus, pimecrolimus, any macrolides such as clindamycin erythromycin
• Current diagnosis or history or any disease, which in the Investigators opinion would contraindicate the use of immunosuppressants, including but not limited to human immunodeficiency virus (HIV) and cancer.
• Use of any nonsteroidal immunosuppressants
• Regular use of intranasal or inhaled corticosteroids, greater than the equivalent of 2 mg of prednisone/day, within 14 days of the first dosing day.
• Use of non-sedating histamines are not allowed for at least 7 days prior to the first dosing day or throughout the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

500 participants in 3 patient groups, including a placebo group

Tacrolimus 0.1% Taro

Experimental group

Description:

Tacrolimus 0.1% manufactured by Taro applied for 14 days

Treatment:

Drug: Tacrolimus 0.1% manufactured by Taro

Protopic - Tacrolimus 0.1%

Active Comparator group

Description:

Protopic, Tacrolimus 0.1% applied for 14 days

Treatment:

Drug: Protopic - Tacrolimus 0.1%

Vehicle

Placebo Comparator group

Description:

Tacrolimus vehicle applied for 14 days

Treatment:

Drug: Tacrolimus Vehicle manufactured by Taro